George Pentheroudakis, Chief Medical Officer at the European Society for Medical Oncology (ESMO), shared on LinkedIn:
“RAS inhibition in pancreatic cancer – an ESMO Express Guideline Update”
Quoting ESMO:
“New ESMO Clinical Practice Guideline Express Update on pancreatic cancer: updated recommendations include daraxonrasib for second-line treatment of metastatic pancreatic cancer”
You can also read: ESMO Clinical Practice Guideline Express Update: Daraxonrasib for Metastatic Pancreatic Cancer
